Factors Associated with the Development of CMV Viremia in High-Risk (D+/R-) Renal Transplant Patients on Valganciclovir Prophylaxis

被引：0
|
作者：
Limaye, A. [1 ]
Hauser, I. [2 ]
Loveless, M. [3 ]
Mu, Y. [3 ]
Blumberg, E. [4 ]
Jardine, A. [5 ]
Humar, A. [6 ]
机构：
[1] U Washington, Seattle, WA USA
[2] Goethe Univ Frankfurt, Frankfurt, Germany
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] U Penn, Philadelphia, PA USA
[5] U Glasgow, Glasgow, Lanark, Scotland
[6] U Alberta, Edmonton, AB, Canada
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2012年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
144
引用
收藏
页码：69 / 69
页数：1
相关论文
共 50 条
  • [31] Human polyomavirus infection is common in cytomegalovirus (CMV) D+/R- solid organ transplant (SOT) patients
    Razonable, RR
    Brown, RA
    Humar, A
    Covington, E
    Alecock, E
    Paya, CV
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 338 - 339
  • [32] COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF 200 DAYS PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) INFECTIONS IN HIGH RISK (D+/R-) KIDNEY TRANSPLANT RECIPIENTS IN POLAND
    Kawalec, P.
    Holko, P.
    Boratynska, M.
    Glyda, M.
    Ignacak, E.
    Russel-Szymczyk, M.
    Szkultecka-Sebek, M.
    Kaweczynska-Lason, A.
    VALUE IN HEALTH, 2011, 14 (07) : A280 - A281
  • [33] COST-EFFECTIVENESS MODEL TO EVALUATE 200-DAY VS 100-DAY TREATMENT WITH VALGANCICLOVIR PROPHYLAXIS TO REDUCE CYTOMEGALOVIRUS DISEASE IN HIGH-RISK (D+/R-) KIDNEY TRANSPLANT RECIPIENT IN SPAIN
    Fernandez-Rivera, C.
    Torre-Cisneros, J.
    Guirado-Perich, L.
    Oyagueez, I
    Ruiz-beato, E.
    VALUE IN HEALTH, 2011, 14 (07) : A275 - A275
  • [34] Risk factors associated to CMV viremia in cardiac transplant patients.: A prospective study
    Delgado, J.
    Manito, N.
    Almenar, L.
    Crespo-Leiro, M.
    Roig, E.
    Segovia, J.
    Vazquez de Prada, J. A.
    Lage, E.
    Palomo, J.
    Camprecios, M.
    Arizon, J. M.
    Rodriguez-Lambert, J. L.
    Blasco, T.
    De La Fuente, L.
    Pascual, D.
    Rabago, G.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2008, 27 (02): : S103 - S104
  • [35] A contrast in the incidence and prevalence of human herpesvirus (HHV)-6 and HHV-7 reactivation in cytomegalovirus (CMV) D+/R- solid organ transplant (SOT) patients receiving oral ganciclovir or valganciclovir prophylaxis
    Razonable, RR
    Brown, RA
    Humar, A
    Covington, E
    Alecock, E
    Paya, CV
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 534 - 535
  • [36] COST-EFFECTIVENESS MODEL TO EVALUATE 200-DAYS VS 100-DAYS TREATMENT WITH VALGANCICLOVIR PROPHYLAXIS TO REDUCE CYTOMEGALOVIRUS DISEASE IN HIGH-RISK (D+/R-) KIDNEY TRANSPLANT RECIPIENT IN SPAIN
    Guirado-Perich, Luis
    Torre-Cisneros, Julian
    Fernandez-Rivera, Constantino
    Oyagueez, Itziar
    Varela, Cristina
    TRANSPLANT INTERNATIONAL, 2011, 24 : 62 - 62
  • [37] Cost Effectiveness of Post-Prophylaxis Screening Strategies for Cytomegalovirus Viremia in CMV D plus R- Kidney Transplant Recipients
    Puttarajappa, C.
    Hariharan, S.
    Smith, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 478 - 478
  • [38] Incidence of CMV Viremia and Disease in Renal Transplant Recipients Utilizing Universal Fixed Low-Dose Valganciclovir Prophylaxis
    Knight, R. J.
    Hong, D.
    Patel, S. J.
    DeVos, J. M.
    Gaber, A. O.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 470 - 470
  • [39] High Rates of Recurrent CMV Infection in D+/R- Liver Transplant Recipients with Pre-emptive Therapy
    Massih, R. Abdel
    Bogdanovich, T.
    Carvalho, F.
    Minces, L.
    Kwak, E.
    Hughes, C.
    Clancy, C.
    Nguyen, M. H.
    Humar, A.
    Silveira, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 468 - 469
  • [40] Impact of Cytomegalovirus Infection in D+/R- Kidney Transplant Patients Receiving Six Months Low Dose Valganciclovir.
    Luan, F. L.
    Kommareddi, M.
    Park, J.
    Ojo, A. O.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 42 - 42
12345